Trifecta™ Valve with Glide™ Technology (GT)

Note to production: I would like to see a printed proof before we send out final to check color of Trifecta product shots. Also need to make sure the final piece doesn’t have a thin black outline on the products. Clients were concerned about that. I told them it’s just the pdf.
The Trifecta™ Valve with Glide™ Technology (GT) combines the best-in-class hemodynamics of the Trifecta™ Valve\textsuperscript{1,6} with ease of placement for challenging anatomies and increased radiopacity for future considerations.
Designed For Challenging Anatomies and Approaches

The Trifecta™ GT valve offers physicians enhanced valve delivery to ease implantation in challenging anatomies, while also offering enhanced visibility and valve protection.

For a minimally invasive approach, choose the Trifecta GT valve for its smaller, more streamlined valve holder, screw-in handle, smooth delivery and single-cut release.

DEMAND EXCELLENCE PLUS EASE OF IMPLANT

The Trifecta™ GT valve features innovations designed to improve handling for more effective placement.

- Soft compliant sewing cuff with minimal needle penetration, suture drag and parachuting forces for smooth valve delivery
- Additional cuff scallop follows the contour of the annulus
- Suture markers aid in optimal needle placement and spacing
- Streamlined conical valve holder for better access and visibility
- Single-cut quick-release holder provides greater efficiency
- Increased radiopacity for future valve considerations

SMOOTHER HANDLING MEANS LESS HANDLING

Designed For Challenging Anatomies and Approaches

The Trifecta™ GT valve offers physicians enhanced valve delivery to ease implantation in challenging anatomies, while also offering enhanced visibility and valve protection.

For a minimally invasive approach, choose the Trifecta GT valve for its smaller, more streamlined valve holder, screw-in handle, smooth delivery and single-cut release.
The Trifecta™ GT valve delivers the same optimal hemodynamic performance of our Trifecta™ valve.11,12

- Large Effective Orifice Areas (EOAs) across all sizes result in decreased prosthesis-patient mismatch and improved quality of life.11-13
- Low transvalvular gradients provide the opportunity for lower rates of heart failure over time.14,15
- Minimal increase in transvalvular gradients under exercise demonstrate excellent exercise hemodynamic tolerance and performance.16-20
- The hydrodynamic performance of the Trifecta™ GT valve is equivalent to that of the Trifecta™ valve.21

### Average Mean Gradient by Valve Size at One Year

<table>
<thead>
<tr>
<th>Valve Size (mm)</th>
<th>n</th>
<th>Mean Gradient (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>66</td>
<td>10.7</td>
</tr>
<tr>
<td>21</td>
<td>160</td>
<td>8.1</td>
</tr>
<tr>
<td>23</td>
<td>197</td>
<td>7.2</td>
</tr>
<tr>
<td>25</td>
<td>135</td>
<td>6.2</td>
</tr>
<tr>
<td>27</td>
<td>40</td>
<td>4.8</td>
</tr>
<tr>
<td>29</td>
<td>15</td>
<td>4.7</td>
</tr>
</tbody>
</table>

### Average Effective Orifice Area by Valve Size at One Year

<table>
<thead>
<tr>
<th>Valve Size (mm)</th>
<th>n</th>
<th>Effective Orifice Area (cm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>66</td>
<td>1.4</td>
</tr>
<tr>
<td>21</td>
<td>151</td>
<td>1.6</td>
</tr>
<tr>
<td>23</td>
<td>190</td>
<td>1.8</td>
</tr>
<tr>
<td>25</td>
<td>129</td>
<td>2.0</td>
</tr>
<tr>
<td>27</td>
<td>38</td>
<td>2.2</td>
</tr>
<tr>
<td>29</td>
<td>13</td>
<td>2.4</td>
</tr>
</tbody>
</table>
DEMONSTRATED LOWER GRADIENTS AMONG STENTED, STENTLESS AND SUTURELESS VALVES

A comparison based on large multicenter, international, prospective studies, submitted by valve manufacturers to the FDA, demonstrates the St. Jude Medical™ Trifecta™ valve has lower average mean gradients size-for-size among stented pericardial and stented porcine valves. In fact, it rivals stentless valves and new sutureless valves.1–6

The nearly cylindric opening of the prosthesis on systole provides gradients and EOAs that surpass any other available stented aortic prosthesis and approach those of stentless prostheses.”

– Bavaria et al.11
Outstanding published freedom from explant due to structural valve deterioration.²²

1. A fatigue-resistant, radiopaque, high-strength titanium stent is designed to reduce stress on leaflets during the cardiac cycle and allows for larger EOAs.⁸,¹¹,²³

2. A pericardial-covered stent to reduce the risk of abrasion and structural valve deterioration.²⁴-²⁶

3. Computer-controlled tissue thickness and fiber orientation.²⁷

4. Additional valve protection on an integral valve holder

5. Linx™ Anticalcification (AC) treatment, a valve treatment that resists calcification four ways.²⁸-³⁴

ENGINEERED FOR LONG-TERM DURABILITY
PEAK PERFORMANCE.
SMOOTH HANDLING.
THE TRIFECTA™ GT VALVE.

Choose the valve that offers peak performance plus smooth handling. The Trifecta™ GT valve gives you exceptional hemodynamics, excellent durability and ultimate confidence during both minimally invasive and conventional procedures.
There is no clinical data currently available that evaluates the long-term impact of anticalcification tissue treatment in humans.

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. Anticalcific and Antidegenerative Treatment of Biological Heart Valves and Coronary Conduits. Edited by Gabbay, S., & Wheatley, D. First Edition, Silent Partners, Inc. 8, 105-113.